Related references
Note: Only part of the references are listed.M6A2Target: a comprehensive database for targets of m6A writers, erasers and readers
Shuang Deng et al.
BRIEFINGS IN BIOINFORMATICS (2021)
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming
Huilong Yin et al.
NATURE COMMUNICATIONS (2021)
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L. A. Emens et al.
ANNALS OF ONCOLOGY (2021)
METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance
Qiang Wang et al.
GUT (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J. A. Kyte et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation
Zhi-Ling Li et al.
NATURE COMMUNICATIONS (2020)
TISIDB: an integrated repository portal for tumor-immune system interactions
Beibei Ru et al.
BIOINFORMATICS (2019)
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Francisco J. Esteva et al.
LANCET ONCOLOGY (2019)
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Han Yao et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Enhancement of LIN28B-induced hematopoietic reprogramming by IGF2BP3
Saifeng Wang et al.
GENES & DEVELOPMENT (2019)
METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner
Jie Han et al.
MOLECULAR CANCER (2019)
Regulation of Gene Expression by N6-methyladenosine in Cancer
Jun Liu et al.
TRENDS IN CELL BIOLOGY (2019)
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Seungwon Yang et al.
NATURE COMMUNICATIONS (2019)
Reading, writing and erasing mRNA methylation
Sara Zaccara et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis
Dan Jin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Reading, writing and erasing mRNA methylation
Sara Zaccara et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g
Xiaoli Cai et al.
CANCER LETTERS (2018)
Checkpoint inhibitors in breast cancer - Current status
Anne Polk et al.
CANCER TREATMENT REVIEWS (2018)
RNA N-6-methyladenosine modification in cancers: current status and perspectives
Xiaolan Deng et al.
CELL RESEARCH (2018)
RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2
Mengnuo Chen et al.
HEPATOLOGY (2018)
Recognition of RNA N6- methyladenosine by IGF2BP proteins enhances mRNA stability and translation
Huilin Huang et al.
NATURE CELL BIOLOGY (2018)
VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation
Yanan Yue et al.
CELL DISCOVERY (2018)
mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis
Junho Choe et al.
NATURE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
RNA modifications modulate gene expression during development
Michaela Frye et al.
SCIENCE (2018)
IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis
Yuhang Zhou et al.
MOLECULAR CANCER (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells
Ly P. Vu et al.
NATURE MEDICINE (2017)
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li et al.
CANCER RESEARCH (2017)
Dynamic RNA Modifications in Gene Expression Regulation
Ian A. Roundtree et al.
CELL (2017)
IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG
S. Samanta et al.
ONCOGENE (2016)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
The m6A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells
Shuibin Lin et al.
MOLECULAR CELL (2016)
m6A RNA methylation promotes XIST-mediated transcriptional repression
Deepak P. Patil et al.
NATURE (2016)
SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features
Yuan Zhou et al.
NUCLEIC ACIDS RESEARCH (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
N6-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions
Nian Liu et al.
NATURE (2015)
Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
Roberto Bellucci et al.
ONCOIMMUNOLOGY (2015)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation
Jianzhao Liu et al.
NATURE CHEMICAL BIOLOGY (2014)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Share Paper
